Connect Biopharma (NASDAQ:CNTB – Get Free Report) had its target price lifted by HC Wainwright from $7.00 to $8.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 426.32% from the stock’s previous close.
Connect Biopharma Price Performance
Shares of CNTB opened at $1.52 on Wednesday. Connect Biopharma has a 12-month low of $0.53 and a 12-month high of $2.84. The firm has a fifty day moving average price of $1.44 and a 200-day moving average price of $1.27.
Institutional Trading of Connect Biopharma
A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its stake in shares of Connect Biopharma by 24.5% during the third quarter. Renaissance Technologies LLC now owns 83,300 shares of the company’s stock valued at $107,000 after purchasing an additional 16,400 shares during the period. Vident Investment Advisory LLC purchased a new stake in Connect Biopharma in the first quarter worth about $55,000. Invesco Ltd. lifted its stake in Connect Biopharma by 135.9% in the first quarter. Invesco Ltd. now owns 60,449 shares of the company’s stock worth $183,000 after acquiring an additional 34,820 shares during the period. Woodline Partners LP purchased a new stake in Connect Biopharma in the first quarter worth about $132,000. Finally, JPMorgan Chase & Co. lifted its stake in Connect Biopharma by 1,312.7% in the first quarter. JPMorgan Chase & Co. now owns 78,547 shares of the company’s stock worth $79,000 after acquiring an additional 72,987 shares during the period. 58.72% of the stock is owned by hedge funds and other institutional investors.
Connect Biopharma Company Profile
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
See Also
- Five stocks we like better than Connect Biopharma
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Comprehensive PepsiCo Stock Analysis
- How to Most Effectively Use the MarketBeat Earnings Screener
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Bear Market Funds to Watch This Year
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.